Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
To the Editor: Although passive surveillance
systems for adverse drug event reporting are often used to detect rare, serious
adverse reactions for marketed drugs, they are limited by underreporting.
The extent of underreporting is unknown and may be influenced by the severity
of the event, the specialty of the reporter, how long the drug has been on
the market, whether the event is labeled, and whether the drug is prescription
or nonprescription.1 We attempted to assess
the degree of underreporting of hemorrhagic stroke associated with phenylpropanolamine,
a nonprescription drug.
La Grenade L, Graham DJ, Nourjah P. Underreporting of Hemorrhagic Stroke Associated With Phenylpropanolamine. JAMA. 2001;286(24):3081. doi:10.1001/jama.286.24.3075